Lipoprotein lipase activator NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin-induced diabetic rats.
NO-1886 is a lipoprotein lipase (LPL) activator. Administration of NO-1886 results in an increase in plasma high-density lipoprotein cholesterol (HDL-C) and a decrease in plasma triglyceride (TG) levels. The aim of this study was to ascertain whether NO-1886 improves fatty liver caused by high-fat feeding in streptozotocin (STZ)-induced diabetic rats. Administration of NO-1886 resulted in increased plasma HDL-C levels and decreased TG levels without affecting total cholesterol and glucose levels in the diabetic rats. NO-1886 dose-dependently decreased liver TG contents and cholesterol contents, resulting in improvement of fatty liver. NO-1886 also reduced plasma aspartate aminotransferase (AST) and alanine aminotransferase (ALT) that accompany fatty liver. The liver cholesterol contents were inversely correlated with plasma HDL-C levels (r = -0.5862, P <.001) and were positively correlated with plasma TG levels (r = 0.4083, P <.003). The liver TG contents were inversely correlated with plasma HDL-C levels (r = -0.6195, P <.001) and were positively correlated with plasma TG levels (r = 0.5837, P <.001). There was no correlation between plasma cholesterol levels, and cholesterol and TG contents in liver. These results indicate that reducing plasma TG levels and elevating in HDL-C levels may result in improving fatty liver.
Kusunoki
Masataka
M
Faculty of Medicine, Aichi Medical University, Aichi, Japan.
Tsutsumi
Kazuhiko
K
Inoue
Yasuhide
Y
Hara
Tsutomu
T
Miyata
Tetsuo
T
Nakamura
Takao
T
Ogawa
Hitoshi
H
Sakakibara
Fumihiko
F
Fukuzawa
Yoshitaka
Y
Okabayashi
Naomi
N
Kato
Koich
K
Ikeda
Hiroshi
H
Kurokawa
Tsuyoshi
T
Ishikawa
Tetsuro
T
Otake
Kazuo
K
Nakaya
Yutaka
Y
D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D001219:Aspartate Aminotransferases / Q000097:blood; D001549:Benzamides / Q000494:pharmacology*; D001786:Blood Glucose / Q000378:metabolism; D001835:Body Weight / Q000187:drug effects; D003921:Diabetes Mellitus, Experimental / Q000150:complications*; D004032:Diet; D004041:Dietary Fats / Q000494:pharmacology*; D020536:Enzyme Activators / Q000494:pharmacology*; D005234:Fatty Liver / Q000139:chemically induced / Q000188:drug therapy*; D008055:Lipids / Q000097:blood; D008071:Lipoprotein Lipase / Q000378:metabolism*; D008297:Male; D009929:Organ Size / Q000187:drug effects; D009943:Organophosphorus Compounds / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar
D001549:Benzamides; D001786:Blood Glucose; D004041:Dietary Fats; D020536:Enzyme Activators; D008055:Lipids; D009943:Organophosphorus Compounds; C082137:4-diethoxyphosphorylmethyl-N-(4-bromo-2-cyanophenyl)benzamide; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D008071:Lipoprotein Lipase